Sign up Australia
Proactive Investors - Run By Investors For Investors

IXICO expands Assessa PML platform pilot to include pharmacovigilance

The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
mri scanner
PML is a rare and potentially fatal disease that affects people living with multiple sclerosis

IXICO Plc (LON:IXI), the digital tech company focussed on neuroscience, has further expanded its pilot of the Assessa progressive multifocal leukoencephalopathy (PML) platform, which includes US biotech giant Biogen Inc (NASDAQ:BIIB).

The Assessa PML platform, which is being trialled in five EU countries, is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect PML, which is a rare and potentially fatal disease that affects people living with multiple sclerosis.

The pilot, which includes platform development and on-boarding of clinical sites, has now been expanded to include pharmacovigilance reporting – monitoring the effects of medical drugs to help identify and evaluate previously unreported adverse reactions.

READ: IXICO technology to be used in Alzheimer's clinical trial

WATCH: Director on conference showcase

Ixico and its partners stand to be paid around £1.5mln to cover the costs of the project, with £0.8mln already being paid out.

Subject to the timing of the work being performed, the AIM-quoted group said the fees support its confidence in delivering revenue growth in the current financial year (to end September).

“We are delighted to announce the expansion of this pilot involving clinical experts in specialist MS centres and Biogen,” said chief executive Giulio Cerroni.

“The Assessa PML digital platform is intended to provide technology and speciality services to physicians involved in delivering care to people living with MS.”

Neuroscience products

IXICO is developing neuroscience products and it is working with the companies it reckons will be the early adopters of its technology – big pharmaceutical companies.

Why are the multi-national drug giants interested in companion products and willing to shell out for them? Simple - very soon these businesses may be paid on results.

The company’s Biogen collaboration is currently in its infancy, but it provides proof positive that IXICO’s strategy has legs.

The plan is not simply to support one company (Biogen), but to provide a solution across a host of drugs to a number of companies.

Expansion on the cards

IXICO aim is to leverage its long-standing expertise in brain scanning and its more recent expansion into collecting data directly from patients, such as with wearable smart watches.

As well as MS, its devices could be deployed to monitor drugs for other neurodegenerative diseases such as Alzheimer’s, Huntingdon’s and Parkinson’s disease.

View full IXI profile View Profile

IXICO Plc Timeline

January 22 2018
December 11 2017
November 16 2017

Related Articles

newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
lupus poster
January 18 2018
The last of the 200 patients has had their final assessment and the data is now being processed and analysed
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use